These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26886442)

  • 1. AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's Disease.
    Ivachtchenko AV; Lavrovsky Y; Ivanenkov YA
    Mol Pharm; 2016 Mar; 13(3):945-63. PubMed ID: 26886442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models.
    Ivachtchenko AV; Ivanenkov YA; Veselov MS; Okun IM
    Curr Alzheimer Res; 2017; 14(3):268-294. PubMed ID: 27829340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation.
    Ivachtchenko AV; Okun I; Aladinskiy V; Ivanenkov Y; Koryakova A; Karapetyan R; Mitkin O; Salimov R; Ivashchenko A
    J Alzheimers Dis; 2017; 58(4):1043-1063. PubMed ID: 28550249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer's Disease.
    Grychowska K; Satała G; Kos T; Partyka A; Colacino E; Chaumont-Dubel S; Bantreil X; Wesołowska A; Pawłowski M; Martinez J; Marin P; Subra G; Bojarski AJ; Lamaty F; Popik P; Zajdel P
    ACS Chem Neurosci; 2016 Jul; 7(7):972-83. PubMed ID: 27100049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Hydroxytryptamine receptor 6 antagonist, SB258585 exerts neuroprotection in a rat model of Streptozotocin-induced Alzheimer's disease.
    Hashemi-Firouzi N; Shahidi S; Soleimani-Asl S; Komaki A
    Metab Brain Dis; 2018 Aug; 33(4):1243-1253. PubMed ID: 29667108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.
    Benhamú B; Martín-Fontecha M; Vázquez-Villa H; Pardo L; López-Rodríguez ML
    J Med Chem; 2014 Sep; 57(17):7160-81. PubMed ID: 24850589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.
    Ivachtchenko AV; Lavrovsky Y; Okun I
    J Alzheimers Dis; 2016 May; 53(2):583-620. PubMed ID: 27232215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.
    Arnt J; Bang-Andersen B; Grayson B; Bymaster FP; Cohen MP; DeLapp NW; Giethlen B; Kreilgaard M; McKinzie DL; Neill JC; Nelson DL; Nielsen SM; Poulsen MN; Schaus JM; Witten LM
    Int J Neuropsychopharmacol; 2010 Sep; 13(8):1021-33. PubMed ID: 20569520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are the Hydantoin-1,3,5-triazine 5-HT
    Lubelska A; Latacz G; Jastrzębska-Więsek M; Kotańska M; Kurczab R; Partyka A; Marć MA; Wilczyńska D; Doroz-Płonka A; Łażewska D; Wesołowska A; Kieć-Kononowicz K; Handzlik J
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31817628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Phenoxyalkyltriazine Antagonists for 5-HT
    Sudoł S; Cios A; Jastrzębska-Więsek M; Honkisz-Orzechowska E; Mordyl B; Wilczyńska-Zawal N; Satała G; Kucwaj-Brysz K; Partyka A; Latacz G; Olejarz-Maciej A; Wesołowska A; Handzlik J
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity.
    Gravius A; Laszy J; Pietraszek M; Sághy K; Nagel J; Chambon C; Wegener N; Valastro B; Danysz W; Gyertyán I
    Behav Pharmacol; 2011 Apr; 22(2):122-35. PubMed ID: 21301322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs.
    Millan MJ; Dekeyne A; Gobert A; Brocco M; Mannoury la Cour C; Ortuno JC; Watson D; Fone KCF
    Neuropharmacology; 2020 Oct; 177():108099. PubMed ID: 32525060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dual-acting 5-HT
    Canale V; Grychowska K; Kurczab R; Ryng M; Keeri AR; Satała G; Olejarz-Maciej A; Koczurkiewicz P; Drop M; Blicharz K; Piska K; Pękala E; Janiszewska P; Krawczyk M; Walczak M; Chaumont-Dubel S; Bojarski AJ; Marin P; Popik P; Zajdel P
    Eur J Med Chem; 2020 Dec; 208():112765. PubMed ID: 32949963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical update on the potential for serotonin 5-HT
    Kucwaj-Brysz K; Baltrukevich H; Czarnota K; Handzlik J
    Bioorg Med Chem Lett; 2021 Oct; 49():128275. PubMed ID: 34311086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of the 5-HT
    de Jong IEM; Mørk A
    Neuropharmacology; 2017 Oct; 125():50-63. PubMed ID: 28711518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.
    Yahiaoui S; Hamidouche K; Ballandonne C; Davis A; de Oliveira Santos JS; Freret T; Boulouard M; Rochais C; Dallemagne P
    Eur J Med Chem; 2016 Oct; 121():283-293. PubMed ID: 27266998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin 5-HT
    Ferrero H; Solas M; Francis PT; Ramirez MJ
    CNS Drugs; 2017 Jan; 31(1):19-32. PubMed ID: 27914038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.
    Wicke K; Haupt A; Bespalov A
    Expert Opin Investig Drugs; 2015; 24(12):1515-28. PubMed ID: 26548316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
    Kołaczkowski M; Marcinkowska M; Bucki A; Śniecikowska J; Pawłowski M; Kazek G; Siwek A; Jastrzębska-Więsek M; Partyka A; Wasik A; Wesołowska A; Mierzejewski P; Bienkowski P
    Eur J Med Chem; 2015 Mar; 92():221-35. PubMed ID: 25557493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.